Preparation method of rifamycin S sodium salt
By directly adding an oxidant to the fermentation broth and combining it with air flotation to separate mycelia, and employing oxidation, acidification, static stratification, and extraction crystallization methods, the instability and high cost of rifamycin S sodium salt preparation process were solved, achieving a simple and efficient preparation process.
Patent Information
- Application Number
- CN202410929459.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-07-11
AI Technical Summary
The existing process for preparing rifamycin S sodium salt has problems such as process instability, complex operation and high cost, especially when fermentation is abnormal, it can easily lead to the waste of filtrate.
The fermentation broth is treated using a combination of oxidation, acidification, air flotation, static stratification, extraction, and crystallization. Oxidizing agents are added directly to the fermentation broth for rapid sterilization, and mycelia are separated by air flotation. Subsequently, extraction is performed using an extractant, and crystallization is adjusted with alkali, thus avoiding the traditional plate and frame filtration steps.
This process achieves stability and ease of operation, reduces wastewater generation, lowers extractant consumption, improves production efficiency, and reduces labor requirements.
Smart Images

Figure CN118878552A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of compound purification and preparation, and particularly relates to a method for preparing rifamycin S sodium salt. Background Art
[0002] Rifamycin antibiotics are a class of broad-spectrum antibiotics, the main varieties of which include rifamycin sodium, rifampicin, rifadin, rifabutin, rifaximin, rifapentine, etc. They are highly active against Mycobacterium tuberculosis and can be used to treat tuberculosis and other diseases caused by drug-resistant mycobacteria. Rifamycin compounds exert their antibacterial effects by inhibiting the activity of bacterial RNA polymerase, thereby preventing bacterial RNA synthesis, and then blocking protein synthesis, ultimately leading to the death of bacteria. Rifamycins are usually used in conjunction with other anti-tuberculosis drugs (such as isoniazid, pyrazinamide, etc.) to reduce the production of drug-resistant strains and improve the therapeutic effect. Due to its broad-spectrum antibacterial effect, rifamycins are sometimes also used to treat other infections, such as brucellosis and lymphoma virus infections.
[0003] Different strains of bacteria can produce rifamycin with different components after fermentation, including A, B, C, D, E, O, S and SV.
[0004] Rifamycin is a semi-synthetic antibiotic, usually extracted by fermentation to obtain the parent rifamycin S sodium salt. Using it as a starting material, rifamycin sodium, rifampicin, rifapentine, rifabutin, etc. are synthesized.
[0005] Rifamycin is fermented by Nocardia mediterranea, and the fermentation liquid is filtered through a plate and frame to remove impurities such as bacterial residue and protein. The filtrate can be subjected to two process flows to obtain rifamycin S sodium salt: (1) adding an oxidant to the filtrate for oxidation, and then extracting with butyl acetate. The extract is subjected to demulsification, washing, concentration, crystallization, centrifugation, and drying to obtain rifamycin S-Na; (2) first extracting rifamycin SV in the filtrate with butyl acetate, and then obtaining rifamycin S through oxidation. The oxidized liquid is subjected to demulsification, washing, concentration, and crystallization to obtain rifamycin S-Na. The difference between the two processes is that the order of extraction and oxidation is different, and the other steps are generally the same.
[0006] However, in the process of removing the bacterial residue through plate and frame filtration, the fermentation liquid is usually pressed into the receiving tank for extraction, and a flocculant is added and stirred. Then it is pressed into the plate and frame filtration. This process takes several hours. Bacteria suffocate and die, decompose and destroy, and metabolize abnormally in this process. When the fermentation is seriously contaminated with bacteria, the filtrate after plate and frame filtration must be used for the next step of extraction. At this time, it is often scrapped in whole or in part because the filtration cannot be performed.
[0007] Therefore, it is necessary to provide a preparation process of rifamycin S sodium salt with good process stability, simple operation and low cost. Summary of the invention
[0008] Purpose of the invention: The technical problem to be solved by the present invention is to provide a method for preparing rifamycin S sodium salt in view of the shortcomings of the prior art.
[0009] In order to solve the above technical problems, the present invention discloses a method for preparing rifamycin S sodium salt, comprising the steps of oxidizing, acidifying and flotating a fermentation liquid containing rifamycin SV in sequence, standing and stratifying the liquid, removing the acid water layer, adding an extractant for extraction, and then separating the solid and liquid, standing and stratifying the obtained liquid, removing the acid water layer, adding an alkali solution to the extractant layer, then adding an alkali to adjust the pH, stirring and crystallizing, and separating and drying to obtain rifamycin S sodium salt.
[0010] The fermentation broth containing rifamycin SV can be derived from a fermentation workshop, and contains mycelium, culture medium and rifamycin SV. In some embodiments, the content of rifamycin SV is generally 0.3% to 0.6%, which is dissolved in the fermentation broth. The solid components of mycelium and culture medium are about 2%, other soluble substances are about 3%, and the rest is water.
[0011] The oxidant used in the oxidation is any one or a mixture of hydrogen peroxide, bleaching powder, sodium hypochlorite, sodium nitrite, trichloroisocyanuric acid, potassium ferrocyanide, chlorine dioxide or peracetic acid; the amount of the oxidant used is calculated by molar number, the ratio of rifamycin s to the oxidant is 1 to 5, and the oxidation time is 2 to 3 hours.
[0012] The acidulant used in the acidification is any one of acetic acid, hydrochloric acid, sulfuric acid or oxalic acid, and the acidulant is added to make the pH of the system be 1-4.
[0013] The flotation is to introduce compressed air and stir. In the process of stirring, the vortex sucking air and the chemical reaction generating gas can also play the role of flotation. The amount of air introduced by the flotation is calculated so that the gas can be wrapped by the liquid. Under normal circumstances, the ventilation volume is 10 to 12 cubic meters of air per cubic meter of liquid per hour. During oxidation and acidification, the air is kept introduced, and the volume of the liquid gradually increases during the process.
[0014] The extractant is any one of butyl acetate, chloroform or dichloromethane, and the amount of the extractant is 10 to 20 times the mass of rifamycin SV.
[0015] The solid-liquid separation adopts any one of a horizontal screw sedimentation centrifuge, an automatic unloading centrifuge or a disc centrifuge.
[0016] The alkali solution added to the extractant layer is a sodium bicarbonate aqueous solution; the alkali used to adjust the pH is sodium hydroxide or sodium carbonate.
[0017] Preferably, a base is added to adjust the pH to 8-12 for stirring crystallization.
[0018] Preferably, after adding alkali to adjust the pH and stirring for crystallization, the temperature is lowered to below 10° C., separated by a centrifuge, and then vacuum dried at below 100° C.
[0019] Beneficial effects: Compared with the prior art, this application has the following advantages:
[0020] (1) By directly adding an oxidant to the fermentation broth, rapid sterilization can be achieved, avoiding the decomposition of unwanted impurities (i.e., homologues of the product, such as deacetyl rifamycin S and demethyl rifamycin S);
[0021] (2) When fermentation is seriously contaminated, the conventional process requires the filtrate to be filtered through a plate and frame before the next step of refining. At this time, the filtrate is often scrapped in whole or in part because the filtration cannot be performed. In this application, the flotation method is used, and since there is no filtration step, the refining can still be carried out normally without being affected;
[0022] (3) Compared with the traditional production method, the present application eliminates the fermentation liquid filtration step, directly oxidizes the fermentation liquid, and uses flotation to separate the mycelium and rifamycin S. After the wastewater is separated, the solid is extracted with an extractant such as butyl acetate or dichloromethane, and only a small amount of wastewater containing organic solvents is produced. The traditional method uses plate and frame filtration, which is labor-intensive and inefficient, producing 1.5 to 2 cubic meters of filtrate per cubic meter of fermentation liquid. All of it is extracted with butyl acetate, which produces a large amount of wastewater containing butyl acetate. The present application greatly reduces the production wastewater of rifamycin, and only 20% of the wastewater of the traditional method contains organic solvents. At the same time, the process of the present invention is suitable for automated production, and the number of personnel used is only 10 to 30% of the traditional method;
[0023] (4) The consumption of the extractant in the present application is also greatly reduced: since the extractant does not come into contact with a large amount of water and is not dissolved in water, the consumption of the extractant is also significantly reduced, which is less than 50% of that in the traditional method. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 The left picture is a schematic diagram of the fermentation liquid under air flotation stirring state, and the right picture is a state diagram of the fermentation liquid after air flotation static separation of acid water;
[0025] Figure 2 This is a liquid phase characterization diagram of rifamycin S prepared in Example 1. In order to clearly show the content of other impurities, the main peak (i.e., rifamycin S) is not fully displayed. DETAILED DESCRIPTION
[0026] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more clear.
[0027] In the following embodiments, the fermentation broth is derived from a fermentation workshop, contains mycelium, culture medium and rifamycin SV, and the rifamycin SV content is 0.3% to 0.6%, dissolved in the fermentation broth. The solid content of mycelium and culture medium is about 2%, other soluble substances are about 3%, and the rest is water. It should be known to those skilled in the art that fermentation broth containing rifamycin SV derived from other fermentation workshops is also applicable to the method of the present application, and the specific properties of the fermentation broth are not limited.
[0028] Example 1 Preparation of Rifamycin S Sodium Salt.
[0029] To 1000L of fermentation liquid containing rifamycin SV, 0.5kg of bleaching powder and 0.4kg of trichloroisocyanuric acid were added for oxidation per kg of rifamycin SV, and air was introduced for stirring and flotation. The ventilation rate was 10 cubic meters of air per cubic meter of liquid per hour. Figure 1 As shown in the left figure. Add 30% hydrochloric acid to acidify to pH 2.5, continue to introduce air during the oxidation and acidification process, and let it stand to separate the acid water. The state of the fermentation liquid after separating the acid water is shown in the figure below. Figure 1 As shown in the right figure. As can be seen from the figure, the water content of the fermentation liquid is greatly reduced after being treated with flotation and stirring for stratification. Add 20kg of butyl acetate for each kg of rifamycin SV and stir. Use a horizontal screw sedimentation centrifuge to separate the solid and liquid, and let the obtained liquid stand for stratification. The lower layer is the acid water layer, and the upper layer is the butyl acetate layer. Remove the acid water layer, add an equal volume of butyl acetate and a 3% sodium bicarbonate as the aqueous phase, adjust the pH to 9.5 with a mass concentration of 5% sodium hydroxide, stir and crystallize, cool to below 10 degrees, separate with a centrifuge, and vacuum dry below 100 degrees to obtain rifamycin S sodium salt.
[0030] The content of the obtained rifamycin S was characterized and detected, and the results are shown in Table 1. Among them, the content detection was determined by external standard method, with reference to high performance liquid chromatography (General Rule 0512). Among them, a C19 stainless steel column, 5μm, a flow rate of 2.0mL / min, an injection volume of 20μL, a detection wavelength of 254nm, and a column temperature of 30°C were used. The mobile phase was mixed with 0.025mol / L disodium hydrogen phosphate (dihydrate)-acetonitrile (51:49), and the pH was adjusted to about 6.9 with phosphoric acid.
[0031] The liquid phase results are shown in Figure 2. Figure 2 shown.
[0032] Table 1
[0033] Inspection items Test results Rifamycin SV 1.82% 25-Deacetyl-27-demethylrifamycin S 0.34% 16-Hydroxymethylrifamycin S 0.51% 27-Demethylrifamycin S 0.67% 25desacetyl rifamycin S 0.77% Sum of peaks (total impurities excluding 25-deacetylrifamycin S) 3.9% Loss on drying (moisture content) 4.9% content 84.7% Solvent impurities 5.33%
[0034] Among them, the total impurities include rifamycin SV, 25-deacetyl-27-demethyl rifamycin S, 16-hydroxymethyl rifamycin S, 27-demethyl rifamycin S and other unlisted impurities.
[0035] Example 2
[0036] The basic steps are the same as those in Example 1, except that 0.1 kg of hydrogen peroxide is used for oxidation per kg of rifamycin SV.
[0037] Example 3
[0038] The basic steps are the same as those in Example 1, except that 0.6 kg of trichloroisocyanuric acid is used for oxidation per kg of rifamycin SV.
[0039] Example 4
[0040] The basic steps are the same as those in Example 1, except that solid oxalic acid is used for acidification to a pH of 3.0, and after flotation and separation of acid water, the solid part is dehydrated to a water content of less than 50% by an automatic unloading centrifuge, butyl acetate is added and stirred, and the butyl acetate layer is separated by standing. An equal volume of 3% sodium bicarbonate water and butyl acetate are added as the aqueous phase, and the pH is adjusted to 9.5 with 5% sodium hydroxide to stir and crystallize, and the temperature is lowered to below 10 degrees and separated by a centrifuge, and vacuum dried below 100 degrees to obtain rifamycin S sodium salt.
[0041] Example 5
[0042] The basic steps are the same as those in Example 1, except that after the acid water is separated by flotation stratification, the solid part is dehydrated to a water content of less than 50% using an automatic unloading centrifuge. 20 kg of chloroform is added to 1 kg of rifamycin SV and stirred, and the stratification is allowed to stand. The chloroform is in the lower layer. After the chloroform is separated, an equal volume of 3% sodium bicarbonate water is added to the chloroform as the aqueous phase, and the pH is adjusted to 9.5 with 5% sodium hydroxide to stir and crystallize, and the temperature is lowered to below 10 degrees to separate using a centrifuge, and vacuum dried below 100 degrees to obtain rifamycin S sodium salt.
[0043] Example 6
[0044] The basic steps are the same as those in Example 2, except that after the acid water is separated by flotation stratification, chloroform is added and stirred. 20 kg of chloroform is added to 1 kg of rifamycin SV and stirred, and the stratification is allowed to stand. The chloroform is in the lower layer. After the chloroform is separated, an equal volume of 3% sodium bicarbonate water is added to the chloroform as the aqueous phase, and the pH is adjusted to 9.5 with 5% sodium hydroxide to stir and crystallize, and the temperature is lowered to below 10 degrees and separated by a centrifuge, and vacuum dried below 100 degrees to obtain rifamycin S sodium salt.
[0045] Example 7
[0046] The basic steps are the same as those in Example 1, except that after the acid water is separated by flotation stratification, dichloromethane is added and stirred. The stratification is static. The dichloromethane is in the lower layer. After the dichloromethane is separated, a 3% sodium bicarbonate solution with an equal volume of dichloromethane is added as the aqueous phase, and the pH is adjusted to 9.5 with 5% sodium hydroxide to stir and crystallize, and the temperature is lowered to below 10 degrees and separated by a centrifuge, and vacuum dried below 100 degrees to obtain rifamycin S sodium salt.
[0047] The test data of each embodiment are shown in Table 1.
[0048] Table 1
[0049]
[0050]
[0051] Comparative Example
[0052] Add 1.5kg zinc sulfate to 1000L fermentation liquid, stir for 10 minutes, and enter the plate and frame filter. After all the fermentation liquid enters the plate and frame, wash it with tap water to 1500L. Check the concentration of the filtrate. Add 1kg bleaching powder and 20kg butyl acetate per kg of rifamycin SV, stir and oxidize with air. After checking that the oxidation is completed, adjust the pH to 1-4 with 30% hydrochloric acid, and separate the water after standing for several hours. After emulsification, add dodecyl trimethylamine chloride, stir and stand, break the emulsification, and separate the water. Wash the butyl acetate solution with tap water, 1% baking soda water, and 1% hydrochloric acid water respectively. Prepare butyl acetate by volume 50%, 3% baking soda water as crystallization water, heat to above 40 degrees, adjust the pH to 9.5 with 5% sodium hydroxide, stir for 2 hours, and cool to below 10 degrees. After standing for several hours, use a centrifuge to filter and separate the solvent. The solid is vacuum dried in a vacuum drying oven at below 100 degrees.
[0053] The content of the obtained rifamycin S was characterized and detected, and the results are shown in Table 2.
[0054] Table 2
[0055]
[0056]
[0057] In summary, this application proposes for the first time a method for preparing sodium salt of rifamycin S that can achieve rapid sterilization and avoid decomposition of unnecessary impurities by directly adding an oxidant to the fermentation broth. There are many methods and approaches to implement this technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention, and these improvements and modifications should also be regarded as the scope of protection of the present invention. All components not specified in this embodiment can be implemented using existing technologies.
Claims
1. A method for preparing rifamycin S sodium salt, characterized in that: The fermentation liquid containing rifamycin SV is oxidized, acidified, and flotated in sequence, and then allowed to stand for stratification. After the acid water is separated, an extractant is added for extraction, and then the solid-liquid separation is performed. The obtained liquid is allowed to stand for stratification, the acid water layer is removed, an alkali solution is added to the extractant layer, and then an alkali is added to adjust the pH, stirred for crystallization, and separated and dried to obtain rifamycin S sodium salt.
2. The preparation method according to claim 1, characterized in that: The oxidant used in the oxidation is any one or a mixture of hydrogen peroxide, bleaching powder, sodium hypochlorite, sodium nitrite, trichloroisocyanuric acid, potassium ferrocyanide, chlorine dioxide or peracetic acid; the amount of the oxidant used is calculated by mole, the ratio of rifamycin s to the oxidant is 1-5, and the oxidation time is 2-3 hours.
3. The preparation method according to claim 1, characterized in that: The acidulant used in the acidification is any one of acetic acid, hydrochloric acid, sulfuric acid or oxalic acid, and the acidulant is added to make the pH of the system 1-4.
4. The preparation method according to claim 1, characterized in that: Flotation is carried out by introducing compressed air and stirring.
5. The preparation method according to claim 1, characterized in that: The extractant is any one of butyl acetate, chloroform or dichloromethane, and the amount of the extractant is 10 to 20 times the mass of rifamycin SV.
6. The preparation method according to claim 1, characterized in that: The solid-liquid separation adopts any one of a horizontal screw sedimentation centrifuge, an automatic unloading centrifuge or a disc centrifuge.
7. The preparation method according to claim 1, characterized in that: The alkali solution added to the extractant layer is a sodium bicarbonate aqueous solution; the alkali used to adjust the pH is sodium hydroxide or sodium carbonate.
8. The preparation method according to claim 1, characterized in that: Add alkali to adjust the pH to 8-12.
9. The preparation method according to claim 1, characterized in that: After adding alkali to adjust the pH and stirring for crystallization, the temperature was lowered to below 10°C and separated by a centrifuge.
10. The preparation method according to claim 1, characterized in that: The drying condition is vacuum drying at below 100°C.
Citation Information
Patent Citations
Fermentation production method of rifamycin SV based on phosphate glycine betaine concentration as control parameter
CN104357586A
Prepn. method of sodium salt for rifainycin s
CN1045993A
Novel rifamycin SV sodium salt production technology
CN105713010A
Rifamycin S-Na salt synthesis method
CN114031628A
Recovery of rieamycin from broths - by oxidn to an insol form
FR2221517A1
